A double-blind, randomized trial of 0.05% betamethasone vs. topical catalase/dismutase superoxide in vitiligo

Journal of the European Academy of Dermatology and Venereology

Volumn 22, Issue 11, 2008, Pages 1359-1364

  Sanclemente, G ^a   Garcia, J J ^a   Zuleta, J J ^a   Diehl, C ^b   Correa, C ^a   Falabella, R ^c  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^c Universidad del Valle

Author keywords

Betamethasone; Catalase dismutase superoxide; RCT; Vitiligo

Indexed keywords

BETAMETHASONE; CATALASE; DISMUTASE SUPEROXIDE; SUPEROXIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ERYTHEMA; FEMALE; HUMAN; MALE; MEDICAL PHOTOGRAPHY; MORPHOMETRICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SKIN DEFECT; VITILIGO;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; BETAMETHASONE; CATALASE; CHILD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; SUPEROXIDE DISMUTASE; VITILIGO;

EID: 53749104935     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2008.02839.x     Document Type: Article

References (21)

1. Roelandts R. Photo(chemo) therapy for vitiligo. Photodermatol Photoimmunol Photomed 2003 19 : 1 4.
2. Sanclemente G, Mahecha M, Guzman C. Enfermedades de la piel más frecuentes de la consulta externa dermatológica del Hospital Universitario San Vicente dePaúl y del Hospital Infantil. Acta Med Colomb 2001 26 : 240 244.
3. Casp CB, She JX, McCormack WT. Genetic association of the catalase gene (CAT) with vitiligo susceptibility. Pigment Cell Res 2002 15 : 62 66.
4. Gauthier Y, Cario AM, Taieb A. A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? Pigment Cell Res 2003 16 : 322 332.
5. Gavalas NG, Akhtar S, Gawkrodger DJ, Watson PF, Weetman AP, Kemp EH. Analysis of allelic variants in the catalase gene in patients with the skin depigmenting disorder vitiligo. Biochem Biophys Res Commun 2006 345 : 1586 1591.
6. Jin Y, Mailloux CM, Gowan K et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 2007 356 : 1216 1225.
7. Park HH, Ha E, Uhm YK et al. Association study between catalase gene polymorphisms and the susceptibility to vitiligo in Korean population. Exp Dermatol 2006 15 : 377 380.
8. Westerhof W, d'Ischia M. Vitiligo puzzle: the pieces fall in place. Pigment Cell Res 2007 20 : 345 359.
9. Ongenae K, Van GN, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003 16 : 90 100.
10. Njoo MD, Westerhof W. Vitiligo. Pathogenesis and treatment. Am J Clin Dermatol 2001 2 : 167 181.
11. Schallreuter KU, Wood JM, Lemke KR, Levenig C. Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. Dermatology 1995 190 : 223 229.
12. Patel DC, Evans AV, Hawk JL. Topical pseudocatalase mousse and narrowband UVB phototherapy is not effective for vitiligo: an open, single-centre study. Clin Exp Dermatol 2002 27 : 641 644.
13. Schallreuter KU, Moore J, Behrens-Williams S, Panske A, Harari M. Rapid initiation of repigmentation in vitiligo with Dead Sea climatotherapy in combination with pseudocatalase (PC-KUS). Int J Dermatol 2002 41 : 482 487.
14. Hartmann A, Brocker EB, Becker JC. Hypopigmentary skin disorders: current treatment options and future directions. Drugs 2004 64 : 89 107.
15. Kandil E. Treatment of vitiligo with 0-1 per cent betamethasone 17-valerate in isopropyl alcohol - a double-blind trial. Br J Dermatol 1974 91 : 457 460.
16. Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvarez MB, Ortiz CA, Torres-Rubalcava AB. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003 139 : 581 585.
17. Naish-Byfield S, Cooksey CJ, Latter AM, Johnson CI, Riley PA. In vitro assessment of the structure-activity relationship of tyrosinase-dependent cytotoxicity of a series of substituted phenols. Melanoma Res 1991 1 : 273 287.
18. Han R, Baden HP, Brissette JL, Weiner L. Redefining the skin's pigmentary system with a novel tyrosinase assay. Pigment Cell Res 2002 15 : 290 297.
19. Vouldoukis I, Lacan D, Kamate C et al. Antioxidant and anti-inflammatory properties of a Cucumis melo LC. extract rich in superoxide dismutase activity. J Ethnopharmacol 2004 94 : 67 75.
20. Barona MI, Arrunategui A, Falabella R, Alzate A. An epidemiologic case-control study in a population with vitiligo. J Am Acad Dermatol 1995 33 : 621 625.
21. Arcos-Burgos M, Parodi E, Salgar M et al. Vitiligo: complex segregation and linkage disequilibrium analyses with respect to microsatellite loci spanning the HLA. Hum Genet 2002 110 : 334 342.